ICUI up +14.54% percent right now. $ICUI High is at 87.50

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2014 at 12:19 PM

ICUI up +14.54% percent right now. $ICUI High is at 87.50 and the Low 80.15 with current volume of 540,314.

Recent News posted below.

ICUI Icu Medical Recent Headline News

Eagle Pharmaceuticals (EGRX) Jumps: Stock Gains 8.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 2 hrs 32 mins ago
Eagle Pharmaceuticals (EGRX) was a big mover last session, with shares rising over 8% on the day.
ICUI: 82.16 (+10.35), ABAX: 53.37 (+0.43), GWPH: 74.55 (+0.60), EGRX: 13.50 (unch)

Upgrade Alert for ICU Medical (ICUI)
Comtex SmarTrend(R) - Tue Nov 11, 6:59AM CST
ICU Medical (NASDAQ:ICUI) was upgraded from Neutral to Buy at Roth Capital today. The stock closed yesterday at $71.81 on volume of 194,000 shares, above average daily volume of 126,000. ICU Medical share prices have moved between a 52-week high of $85.00 and a 52-week low of $35.58 and closed yesterday at 102% above that low price at $71.81 per share. The 200-day and 50-day moving averages have moved 0.16% higher and 0.83% higher over the past week, respectively.
ICUI: 82.16 (+10.35)

ICU Medical posts 3Q profit
Automated Insights - Tue Nov 11, 4:11AM CST
SAN CLEMENTE, Calif. (AP) _ ICU Medical Inc. (ICUI) on Tuesday reported profit of $6.4 million in its third quarter.
ICUI: 82.16 (+10.35)

ICU Medical's (ICUI) CEO Vivek Jain on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 6:51PM CST

ICUI: 82.16 (+10.35)

ICU Medical beats by $0.18, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:32PM CST

ICUI: 82.16 (+10.35)

ICU Medical (ICUI) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 10, 3:25PM CST

ICUI: 82.16 (+10.35)

ICU Medical, Inc. Announces Third Quarter 2014 Results
GlobeNewswire - Mon Nov 10, 3:11PM CST
ICU Medical, Inc., (Nasdaq:ICUI) ("ICU Medical"

, a leader in innovative medical devices used in vascular therapy, oncology and critical care applications, today announced financial results for the third quarter and nine months ended September 30, 2014.
ICUI: 82.16 (+10.35)

Walgreens Hits the Rock with Court's Ruling on CFO Lawsuit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 2:30PM CST
The controversy surrounding an inflated fiscal 2016 earnings forecast continues for leading drugstore chain Walgreen Co. (WAG).
BSX: 13.44 (-0.01), ICUI: 82.16 (+10.35), ABAX: 53.37 (+0.43), WAG: 67.61 (-0.17)

Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:35PM CST

HK: 2.89 (-0.36), WWD: 48.11 (-3.70), LLNW: 2.66 (+0.16), FXEN: 2.71 (-0.14), RMTI: 11.17 (+0.27), CZR: 11.18 (-0.36), EGY: 6.82 (-0.17), ICUI: 82.16 (+10.35), ICEL: 7.53 (-0.17), SAAS: 9.16 (+0.19), DMD: 5.73 (-1.40), NPSP: 29.26 (+2.35), SCLN: 8.14 (+0.04), ATHX: 1.51 (-0.03), CMLS: 3.11 (-0.18), TC: 2.16 (+0.20), ATW: 36.28 (-1.48), CLUB: 6.07 (-0.70), RAX: 42.25 (+4.93), PTLA: 27.50 (-0.15), IPAR: 29.08 (-0.14), ATLS: 37.00 (+0.13), AMBC: 24.38 (+1.01), CUI: 8.50 (+0.08), PDLI: 8.10 (+0.17), OMER: 18.58 (+1.09), PRAA: 61.69 (-2.16), CARA: 8.55 (-0.20), HALO: 8.83 (-0.49), MODN: 10.63 (+0.53), CALL: 8.68 (-1.81), ASEI: 48.50 (-7.59), HGR: 20.88 (+0.29), ERII: 4.41 (-0.57)

BioScrip (BIOS) Q3 Loss Wider than Expected, Revenues Top - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:10PM CST
BioScrip, Inc. (BIOS) recently declared its third-quarter 2014 results.
BSX: 13.44 (-0.01), ICUI: 82.16 (+10.35), ABAX: 53.37 (+0.43), BIOS: 5.70 (+0.11)

Omnicell Earnings Hit by High Tax, User Addition Aids Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 11:27AM CST
On Nov 7, 2014, we issued an updated research report on Omnicell Inc. (OMCL).
BSX: 13.44 (-0.01), ICUI: 82.16 (+10.35), ABAX: 53.37 (+0.43), OMCL: 31.93 (-0.56)

Strength Seen in Hospira (HSP): Stock Moves 6.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:25AM CST
Hospira (HSP) was a big mover last session, with shares rising nearly 7% on the day.
ICUI: 82.16 (+10.35), ABAX: 53.37 (+0.43), GWPH: 74.55 (+0.60), HSP: 56.72 (+0.74)

Strength Seen in Sophiris Bio (SPHS): Stock Soars 25% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:46AM CST
Sophiris Bio (SPHS) was a big mover last session, as the company saw its shares surge 25% on the day.
ICUI: 82.16 (+10.35), ABAX: 53.37 (+0.43), GWPH: 74.55 (+0.60), SPHS: 2.70 (-0.05)

Rockwell Medical (RMTI) Worth Watching: Stock Surges 21.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:25AM CST
Rockwell Medical (RMTI) was a big mover last session, as the company saw its shares surge over 21% on the day.
ICUI: 82.16 (+10.35), ABAX: 53.37 (+0.43), GWPH: 74.55 (+0.60), RMTI: 11.17 (+0.27)

CVS Health Beats Q3 Earnings, Revenues; Narrows Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 1:00PM CST
CVS Health Corporation (CVS) ??? formerly known as CVS Caremark ??? reported third-quarter 2014 adjusted earnings per share (EPS) of $1.15.
BSX: 13.44 (-0.01), ICUI: 82.16 (+10.35), ABAX: 53.37 (+0.43), CVS: 89.90 (+0.71)

Haemonetics Q2 Earnings Beat Estimates but Decline Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 12:20PM CST
Haemonetics Corporation (HAE) reported adjusted earnings of 47 cents per share in the second quarter of fiscal 2015.
BSX: 13.44 (-0.01), ICUI: 82.16 (+10.35), ABAX: 53.37 (+0.43), HAE: 36.89 (+0.23)

14.1% Return Seen to Date on SmarTrend ICU Medical Call (ICUI)
Comtex SmarTrend(R) - Tue Nov 04, 11:13AM CST
SmarTrend identified an Uptrend for ICU Medical (NASDAQ:ICUI) on August 12th, 2014 at $62.20. In approximately 3 months, ICU Medical has returned 14.13% as of today's recent price of $70.99.
ICUI: 82.16 (+10.35)

Cardiovascular Systems (CSII) Jumps: Stock Rises 6.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:46AM CST
Cardiovascular Systems (CSII) was a big mover last session, with shares rising over 6% on the day.
ICUI: 82.16 (+10.35), CSII: 29.85 (-0.17), ABAX: 53.37 (+0.43), GWPH: 74.55 (+0.60)

Strength Seen in AtriCure (ATRC): Stock Gains 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:25AM CST
AtriCure (ATRC) was a big mover last session, with shares rising nearly 7% on the day.
ICUI: 82.16 (+10.35), ABAX: 53.37 (+0.43), GWPH: 74.55 (+0.60), ATRC: 17.76 (+0.07)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ASTS Faces Crucial Deadline Amidst Legal Turmoil

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Darden Faces Class Action Over Reimbursement Failures

Class Action Puts Darden Restaurants in Legal Hot Seat Darden Restaurants, Inc. is staring down the barrel of a lawsuit that's as fiery as a grill on a Saturday night rush. The legal cavalry from Blumenthal Nordrehaug Bhowmik De Blouw LLP has stormed in with a class action complaint, aiming dead center at Darden for allegedly breaching the California Labor Code. In plain...

Alaska's Insurance Maze: Coverage Over Cheap Policies

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

DIRECTV Bags New NHL Deals: Stakes for Sports Fans

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Likang's Bold Move: Cancer Immunotherapy at AD Summit

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

World Young Scientist Summit 2026 in Wenzhou Kicks Off

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Aluminum Design Fumble: Geometry Over Wall Thickness

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...